Apollomics Inc Cl A (APLM)

$5.45 -0.25 (-4.39%)
Market Cap 6.29M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 13,300
Avg Vol 16,294
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 23%
Beta 0.93
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
Love_To_Learn
Love_To_Learn Jul. 10 at 6:04 PM
$CDT $APLM will need u 2 as well
0 · Reply
Pitts123
Pitts123 Jul. 9 at 6:58 PM
$APLM Did this get halted?
1 · Reply
_www_larval_com_
_www_larval_com_ Jul. 9 at 1:42 PM
$KZIA 9%[41%] $SY 8%[2%] $APLM -8%[-11%] $BMNR -8%[-3%] $MPU -8%[-3%] most notable movement within the first minutes of trading.
0 · Reply
TheInside2028
TheInside2028 Jul. 9 at 1:18 PM
$APLM bought tier 1
0 · Reply
hrule93
hrule93 Jul. 9 at 12:58 PM
$APLM make pumpers regret selling this morning
0 · Reply
Elgrecoss
Elgrecoss Jul. 9 at 11:47 AM
$APLM looks like it’s coming back
0 · Reply
BleedinJaysus
BleedinJaysus Jul. 9 at 11:09 AM
$APLM wow what a scam. Was fun to watch that rug pull in real time. Shame on pumpers
0 · Reply
LongDuckDongFever2020
LongDuckDongFever2020 Jul. 9 at 10:58 AM
$APLM 3384 shares avg 6.35 after falling for pump. co has plenty of cash
0 · Reply
Bigblock6
Bigblock6 Jul. 9 at 10:41 AM
$APLM Am i missing something here the stock got smacked amd people are saying its going to run
0 · Reply
101obrien
101obrien Jul. 9 at 10:27 AM
$APLM Congrats to the pumpers and influencers. Watched it run and waited for pullback, entered at $6.30, just over the recent POC. Didnt see it selling off to 120 POC lecel. Well played whoever coordinated this.
0 · Reply
Latest News on APLM
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 3 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 7 months ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 7 months ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 11 months ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 11 months ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 11 months ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 1 year ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 1 year ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 1 year ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 1 year ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 1 year ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 1 year ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 1 year ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 1 year ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Love_To_Learn
Love_To_Learn Jul. 10 at 6:04 PM
$CDT $APLM will need u 2 as well
0 · Reply
Pitts123
Pitts123 Jul. 9 at 6:58 PM
$APLM Did this get halted?
1 · Reply
_www_larval_com_
_www_larval_com_ Jul. 9 at 1:42 PM
$KZIA 9%[41%] $SY 8%[2%] $APLM -8%[-11%] $BMNR -8%[-3%] $MPU -8%[-3%] most notable movement within the first minutes of trading.
0 · Reply
TheInside2028
TheInside2028 Jul. 9 at 1:18 PM
$APLM bought tier 1
0 · Reply
hrule93
hrule93 Jul. 9 at 12:58 PM
$APLM make pumpers regret selling this morning
0 · Reply
Elgrecoss
Elgrecoss Jul. 9 at 11:47 AM
$APLM looks like it’s coming back
0 · Reply
BleedinJaysus
BleedinJaysus Jul. 9 at 11:09 AM
$APLM wow what a scam. Was fun to watch that rug pull in real time. Shame on pumpers
0 · Reply
LongDuckDongFever2020
LongDuckDongFever2020 Jul. 9 at 10:58 AM
$APLM 3384 shares avg 6.35 after falling for pump. co has plenty of cash
0 · Reply
Bigblock6
Bigblock6 Jul. 9 at 10:41 AM
$APLM Am i missing something here the stock got smacked amd people are saying its going to run
0 · Reply
101obrien
101obrien Jul. 9 at 10:27 AM
$APLM Congrats to the pumpers and influencers. Watched it run and waited for pullback, entered at $6.30, just over the recent POC. Didnt see it selling off to 120 POC lecel. Well played whoever coordinated this.
0 · Reply
jaj89
jaj89 Jul. 9 at 10:22 AM
$APLM good job pumpers and spammers
0 · Reply
beacher
beacher Jul. 9 at 10:20 AM
$APLM starting a small position here
3 · Reply
LongDuckDongFever2020
LongDuckDongFever2020 Jul. 9 at 10:12 AM
$APLM every single handle here that pumped this before 1 share of volume hit will be referred to FINRA for action.
0 · Reply
Elgrecoss
Elgrecoss Jul. 9 at 10:02 AM
$APLM why is it dropping so much? Does anybody know????
1 · Reply
VMAESA
VMAESA Jul. 9 at 10:01 AM
$APLM lmao
1 · Reply
MomentumZeus
MomentumZeus Jul. 9 at 9:57 AM
Nailed $APLM for insane profits! Lovely $6.70 entry and we hit $11+ Premarket! Make sure to hit that Follow if you also banked!
7 · Reply
Johnny50ish
Johnny50ish Jul. 9 at 9:56 AM
$APLM shouldn't this be going up lol
0 · Reply
Red2Profit
Red2Profit Jul. 9 at 9:53 AM
$APLM Wow I forecasted this algo spike last night thanks to @LegendaryCharts
1 · Reply
Uwotm8E
Uwotm8E Jul. 9 at 9:51 AM
$APLM
0 · Reply
CerebralKobe
CerebralKobe Jul. 9 at 9:48 AM
$BABA $SBET $SPY $META >> $APLM send it!
0 · Reply
MomentumZeus
MomentumZeus Jul. 9 at 9:47 AM
$APLM Massive breakout here! Insane momentum!
1 · Reply
BullishTetrix
BullishTetrix Jul. 9 at 9:45 AM
$APLM going to 12+ loads of cash
0 · Reply